SOURCE: Aldagen

May 22, 2007 09:00 ET

Aldagen Expands Board of Directors

Dr. Martin J. Murphy, Jr. Is Widely Recognized Thought Leader in Stem Cells and Cancer

DURHAM, NC -- (MARKET WIRE) -- May 22, 2007 --Aldagen, Inc., a biotechnology company advancing a pipeline of clinical-stage regenerative therapies, today announced the appointment of Dr. Martin J. Murphy, Jr. to its Board of Directors. This addition will bring Aldagen's Board to 5 members.

Dr. Murphy is the Founding Chairman and Chief Executive Officer of AlphaMed Consulting, Inc., a corporation that provides strategic support for academic cancer centers and cancer drug development programs for global pharmaceutical and biotechnology companies. He is Founding Executive Editor of the international, peer-reviewed journals "Stem Cells" and "The Oncologist." As founder and former Chief Executive Officer of the Hipple Cancer Research Center, Dr. Murphy was professor of medicine and principal investigator of $21 million of grants and research contracts. Dr. Murphy is a member of the Scientific Advisory Boards of Pappas Ventures and Almac Diagnostics. He is a member of the board of trustees of the American Cancer Society Foundation, a director of the Foundation for the National Institutes of Health (FNIH), a director of Jennerex Pharmaceuticals, and a charter member of C-Change (formerly, the National Dialogue on Cancer). At the request of former President George Bush, Marty has been convener of the non-profit CEO Roundtable on Cancer since its origin in 2001.

"Marty is both an accomplished entrepreneur and a widely recognized thought leader in stem cells. He brings a valuable network of physicians and scientists within top-tier research institutes that will help us advance current products as well as develop new product opportunities," said Tom Amick, Chairman and Chief Executive Officer of Aldagen. "I look forward to working closely with Marty to leverage his vast experience and network to help guide us through successfully advancing our products through the clinic."

"Aldagen is fortunate to have both a powerful and promising scientific portfolio as well as superb leadership," Dr. Murphy said. "This is a winning combination in biotechnology and that's why I feel blessed to have been invited to join Aldagen's board at a time when its clinical impacts are just beginning to emerge."

About Aldagen, Inc.

ALDAGEN is a biotechnology company advancing a pipeline of clinical-stage regenerative therapies. The Company has three product candidates in clinical development for chronic heart failure, critical limb ischemia and pediatric metabolic disorders and malignancies. ALDAGEN's therapeutics are produced by a proprietary technology platform that selects potent, adult stem and progenitor cells for therapeutic use. The platform yields a broad range of therapeutic cells that can be used rapidly, without culture or expansion. To learn more about ALDAGEN, please visit

Contact Information